KR102386659B9 - New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof - Google Patents

New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Info

Publication number
KR102386659B9
KR102386659B9 KR1020210149720A KR20210149720A KR102386659B9 KR 102386659 B9 KR102386659 B9 KR 102386659B9 KR 1020210149720 A KR1020210149720 A KR 1020210149720A KR 20210149720 A KR20210149720 A KR 20210149720A KR 102386659 B9 KR102386659 B9 KR 102386659B9
Authority
KR
South Korea
Prior art keywords
stem cell
protection effect
new compounds
medium composition
culturing stem
Prior art date
Application number
KR1020210149720A
Other languages
Korean (ko)
Other versions
KR20210135449A (en
KR102386659B1 (en
Inventor
권상모
박지혜
문형룡
정해영
Original Assignee
부산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부산대학교 산학협력단 filed Critical 부산대학교 산학협력단
Priority to KR1020210149720A priority Critical patent/KR102386659B1/en
Publication of KR20210135449A publication Critical patent/KR20210135449A/en
Application granted granted Critical
Publication of KR102386659B1 publication Critical patent/KR102386659B1/en
Publication of KR102386659B9 publication Critical patent/KR102386659B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020210149720A 2020-03-09 2021-11-03 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof KR102386659B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210149720A KR102386659B1 (en) 2020-03-09 2021-11-03 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200029271A KR102367101B1 (en) 2020-03-09 2020-03-09 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof
KR1020210149720A KR102386659B1 (en) 2020-03-09 2021-11-03 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020200029271A Division KR102367101B1 (en) 2020-03-09 2020-03-09 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Publications (3)

Publication Number Publication Date
KR20210135449A KR20210135449A (en) 2021-11-15
KR102386659B1 KR102386659B1 (en) 2022-04-14
KR102386659B9 true KR102386659B9 (en) 2022-12-05

Family

ID=77924172

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020200029271A KR102367101B1 (en) 2020-03-09 2020-03-09 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof
KR1020210149720A KR102386659B1 (en) 2020-03-09 2021-11-03 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020200029271A KR102367101B1 (en) 2020-03-09 2020-03-09 New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof

Country Status (1)

Country Link
KR (2) KR102367101B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4209773A4 (en) 2021-08-27 2024-05-08 Lg Chem, Ltd. System and method for predicting physical properties of multilayer material
KR20230140068A (en) 2022-03-29 2023-10-06 고려대학교 산학협력단 Composition for culturing Organoid inducing Reserve stem cell and Culture method using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101358777B1 (en) 2013-04-30 2014-02-10 서울대학교병원 Adult stem cells originated from endocardium and method for producing them
KR102037823B1 (en) 2013-08-09 2019-10-29 서울대학교산학협력단 Method for mass preparing of vasculogenic factors using stem cell aggregate, and use thereof
KR102182513B1 (en) 2017-06-30 2020-11-25 인제대학교 산학협력단 Formulation of human derived cardiac stem cell spheroids and application thereof
WO2019043706A1 (en) 2017-08-31 2019-03-07 Bar-Ilan University Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer

Also Published As

Publication number Publication date
KR102367101B1 (en) 2022-02-23
KR20210135449A (en) 2021-11-15
KR102367101B9 (en) 2022-12-05
KR20210113915A (en) 2021-09-17
KR102386659B1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
KR102386659B9 (en) New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof
EP3947642A4 (en) Culture medium for mammalian expanded potential stem cells, composition, and methods thereof
WO2010111422A3 (en) Induced pluripotent stem cell generation using two factors and p53 inactivation
IL201225A0 (en) Method for evaluating the composition of a cell culture and cell phenotype
BR112013001089A2 (en) culture medium composition and method for cultivating ammonium-derived mesenchymal stem cells
IL288260A (en) Compositions and methods for plant cell culture
EP2995677A4 (en) Culture medium composition for improving regenerative capacity of stem cells, and stem cell culturing method using same
EP3733834C0 (en) Scaffolding material for stem cell cultures and stem cell culture method using same
EP2228435A4 (en) Method for amplification of hematopoietic stem cell using heterocyclic compound
IL290134A (en) Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors
IL286776A (en) Compositions and methods for preparing t cell compositions and uses thereof
IL286907A (en) Cryopreservation and cell culture media
BR112014000042A2 (en) composition, cell culture medium, use of a composition, and method for culturing cells
EP4291208A4 (en) Modified stem cell compositions and methods for use
EP2218716A4 (en) Method for amplifying hematopoietic stem cells using heterocyclic compound
WO2010138750A3 (en) Generation of genetically corrected disease-free induced pluripotent stem cells
EP2233561A4 (en) Method for amplification of hematopoietic stem cell using heterocyclic compound
EP3962267A4 (en) Composition and method for cryopreservation of cells
EP3862429A4 (en) Composition for extending telomere of cell and preparation method therefor
IL287387A (en) Cell culture medium for eukaryotic cells
KR102325857B9 (en) T composition for culturing regulatory t cell and use thereof
EP4196133A4 (en) Methods and compositions for stimulating gamma delta t cells
EP4102961A4 (en) Methods and compositions for multiplexed editing of plant cell genomes
EP4051782A4 (en) Medium and methods for culturing organoids
EP3956440A4 (en) A new type of enzyme composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]